Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

Author： Bendtzen Klaus   Ainsworth Mark   Steenholdt Casper   Thomsen Ole Østergaard   Brynskov Jørn  

Publisher： Informa Healthcare

ISSN： 0036-5521

Source： Scandinavian Journal of Gastroenterology, Vol.44, Iss.7, 2009-07, pp. : 774-781

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis

By  

Current Vascular Pharmacology, Vol. 8, Iss. 2, 2010-01 ,pp. : 285-292

Bentham Science Publishers

Access to resources Recommend Favorite

Patient’s Perspectives Important for Early Anti-Tumor Necrosis Factor Treatment in Inflammatory Bowel Disease

By  

Digestion, Vol. 79, Iss. 1, 2009-02 ,pp. : 30-35

Karger

Access to resources Recommend Favorite

Is There a Role for Therapeutic Drug Monitoring of Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease

By  

Digestive Diseases, Vol. 33, Iss. 1, 2015-09 ,pp. : 70-77

Karger

Access to resources Recommend Favorite

Tumour Necrosis Factor Alpha Antibody Affects Gastrin Release in Crohn Disease

By Hopman W. P. M.   Jong D. J. de   Naber A. H. J.   Jansen J. B. M. J.  

Scandinavian Journal of Gastroenterology, Vol. 38, Iss. 5, 2003-01 ,pp. : 522-525

Informa Healthcare

Access to resources Recommend Favorite

Staphylococcus aureus thymic abscesses associated with anti-tumour necrosis factor therapy

By Osiri M.   Tantawichien T.  

Scandinavian Journal of Rheumatology, Vol. 36, Iss. 4, 2007-01 ,pp. : 320-321

Informa Healthcare

Access to resources Recommend Favorite